Traders should monitor how Xenon allocates the capital, particularly progress in Phase 3 trials for azetukalner; the large cash infusion strengthens the balance sheet but introduces near-term dilution.
XENE drugs
XENE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 13 $55.23entry
- T+1 · 8mo ago −1.03%α −2.06% · $54.66
- T+5 · 8mo ago −0.53%α +1.59% · $54.94
- T+20 · 7mo ago +6.10%α +2.51% · $58.60
- T+60 · 5mo ago −7.28%α −18.89% · $51.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xenon Pharmaceuticals closed a public offering of 12,236,843 common shares and pre-funded warrants to purchase 877,194 additional shares, raising approximately $747.5 million in gross proceeds. The offering was priced at $57.00 per common share, with pre-funded warrants sold at $56.9999 and an exercise price of $0.0001 per warrant.
Key Financial Metrics
Key Facts
- Xenon raised approximately $747.5 million in gross proceeds from the offering.
- The offering included 12,236,843 common shares and pre-funded warrants for 877,194 additional shares.
- Common shares were priced at $57.00; pre-funded warrants were priced at $56.9999 with a nominal exercise price of $0.0001.
- The underwriters' option to purchase additional shares was fully exercised.
- Proceeds will be used for general corporate purposes, including R&D for azetukalner and other pipeline programs.
- No securities were sold in Canada or to Canadian residents.
Financial Impact
$747.5 million in gross proceeds, resulting in moderate dilution for existing shareholders
Risk Factors
- Dilution from issuance of new shares and potential future exercises of pre-funded warrants.
- Execution risk in clinical development, particularly for the lead asset azetukalner in multiple indications.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255083 |
Track record
19 reports on XENE
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers